Physician profile
Mohammad Sameer Zaheerullah
NPI 1295978526
$5,736.73
in general payments reported to CMS, 2019-2025
22 companies · $2,117 in 2025
The $2,117 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.52 · 2022: $653 · 2023: $1,124 · 2024: $1,776 · 2025: $2,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,989 · Travel and Lodging: $838 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,988.56 |
| Travel and Lodging | $837.72 |
| Education | $189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,343.57 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $840.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $788.13 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Avadel Cns Pharmaceuticals, LLC | $559.34 | 2023-2025 | Lumryz |
| Glaxosmithkline, LLC. | $419.19 | 2022-2025 | Nucala, Trelegy Ellipta |
| Olympus Corporation of The Americas | $348.96 | 2025 | |
| Insmed, INC. | $259.32 | 2023-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $229.30 | 2021-2025 | Opsumit, Uptravi |
| Electromed, INC. | $182.42 | 2022-2025 | Smartvest |
| Pulmonx Corporation | $154.01 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Genzyme Corporation | $153.98 | 2022-2024 | |
| Amgen INC. | $84.58 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $83.43 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $47.14 | 2023-2025 | Zerbaxa |
| Ani Pharmaceuticals, INC. | $46.56 | 2024-2025 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.25 | 2023-2024 | Ofev |
| Verona Pharma, INC. | $39.84 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $36.50 | 2023 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $24.85 | 2025 | Glassia |
| Genentech USA, INC. | $23.27 | 2025 | Xolair |
| Philips North America LLC | $14.30 | 2025 | Vest Therapy Und |
| Inogen, INC. | $14.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Zaheerullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.